Below is quote on Sun pharma by Mr. Yash Gupta, Equity Research Associate, Angel Broking Ltd
Sun Pharmaceuticals reported a good set of numbers for Q1FY2022, posting revenue growth of 30% at ₹9669.4 crores in Q1FY2022 which is above the market expectations. The domestic market has done well for the company in this quarter up by 38.5%. We have seen strong growth reported by all the pharma companies on the back of a recovery in the acute therapeutic segment. We expect domestic growth momentum to continue in this financial year. US formulation market reported growth of 30% which is above the market expectations. The overall company reported one of the best quarterly results in a very long time. We have a positive outlook on Sun Pharmaceuticals Ltd.
Above views are of the author and not of the website kindly read disclaimer